METMED: Metformin for cognitive and brain recovery in children treated for a brain tumour

Abstract

The purpose of this study is to test whether metformin treatment is associated with greater improvement of cognitive function and brain growth compared to placebo group for children/adolescents with a brain tumour.

Who is it for? You may be eligible to participate in this study if you are between 7 years and 21 years and 11 months old and have been treated for a brain tumour.

Study Details Participants will be required to take oral medication in tablet form daily for 16 weeks. 'Participants will be randomly allocated to receive either metformin as an oral tablet taken daily or a placebo tablet. Participation in this trial will require an overall time commitment of 40 weeks as participants must undergo screening and pre-treatment assessments and as well as a 6 month post-treatment follow-up. Assessments will include MRI scans and cognitive testing to measure memory, attention and processing speed.

It is hoped that this research will help to determine if metformin has a positive effect on cognitive and brain recovery from brain cancer in this population